Hmdb loader
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:50 UTC
Update Date2021-09-14 15:42:54 UTC
HMDB IDHMDB0014728
Secondary Accession Numbers
  • HMDB14728
Metabolite Identification
Common NameDoxazosin
DescriptionDoxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland.
Structure
Data?1582753214
Synonyms
ValueSource
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazinChEBI
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazinChEBI
DoxazosinaChEBI
DoxazosineChEBI
DoxazosinumChEBI
Cardura XLKegg
Doxazosin mesilateHMDB
Alter brand OF doxazosin mesylateMeSH, HMDB
Apogepha brand OF doxazosin mesylateMeSH, HMDB
AstraZeneca brand OF doxazosin mesylateMeSH, HMDB
CarduraMeSH, HMDB
Ciclum brand OF doxazosin mesylateMeSH, HMDB
combino Brand OF doxazosin mesylateMeSH, HMDB
Doxa purenMeSH, HMDB
DoxacorMeSH, HMDB
Doxazosin alMeSH, HMDB
Doxazosin findusfitMeSH, HMDB
Doxazosina geminisMeSH, HMDB
Geminis brand OF doxazosin mesylateMeSH, HMDB
Gen doxazosinMeSH, HMDB
Heumann brand OF doxazosin mesylateMeSH, HMDB
Juta brand OF doxazosin mesylateMeSH, HMDB
JutalarMeSH, HMDB
Kade brand OF doxazosin mesylateMeSH, HMDB
Linden brand OF doxazosin mesylateMeSH, HMDB
MTW DoxazosinMeSH, HMDB
neo, CarduranMeSH, HMDB
Stadapharm brand OF doxazosinMeSH, HMDB
TAD brand OF doxazosin mesylateMeSH, HMDB
UriductMeSH, HMDB
FindusFit brand OF doxazosin mesylateMeSH, HMDB
ratio-DoxazosinMeSH, HMDB
AlfamedinMeSH, HMDB
Almirall brand OF doxazosin mesylateMeSH, HMDB
Alpharma brand OF doxazosin mesylateMeSH, HMDB
Cantabria brand OF doxazosin mesylateMeSH, HMDB
DiblocinMeSH, HMDB
DoxatensaMeSH, HMDB
Doxazosin mesylateMeSH, HMDB
Doxazosin wolffMeSH, HMDB
Doxazosin ratiopharmMeSH, HMDB
Doxazosin-wolffMeSH, HMDB
Doxazosin-ratiopharmMeSH, HMDB
Doxazosina normonMeSH, HMDB
Doxazosina pharmagenusMeSH, HMDB
Genpharm brand OF doxazosin mesylateMeSH, HMDB
Hexal brand OF doxazosin mesylateMeSH, HMDB
Merck dura brand OF doxazosin mesylateMeSH, HMDB
Monohydrochloride, doxazosinMeSH, HMDB
novo DoxazosinMeSH, HMDB
Progandol neoMeSH, HMDB
Q-Pharm brand OF doxazosin mesylateMeSH, HMDB
ZoxanMeSH, HMDB
CT-Arzneimittel brand OF doxazosin mesylateMeSH, HMDB
Doxazosin von CTMeSH, HMDB
Aliud brand OF doxazosin mesylateMeSH, HMDB
Apotex brand OF doxazosin mesylateMeSH, HMDB
CardularMeSH, HMDB
Carduran neoMeSH, HMDB
Cinfa brand OF doxazosin mesylateMeSH, HMDB
DoxagammaMeSH, HMDB
Doxazosin heumannMeSH, HMDB
Doxazosin monohydrochlorideMeSH, HMDB
Doxazosin betaMeSH, HMDB
Doxazosina combino pharmMeSH, HMDB
Doxazosina ratiopharmMeSH, HMDB
Doxazosina urMeSH, HMDB
Gen-doxazosinMeSH, HMDB
MTW-DoxazosinMeSH, HMDB
Normon brand OF doxazosin mesylateMeSH, HMDB
Ratiopharm brand OF doxazosin mesylateMeSH, HMDB
Solvay brand OF doxazosin mesylateMeSH, HMDB
ratio DoxazosinMeSH, HMDB
1 (4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazineMeSH, HMDB
apo DoxazosinMeSH, HMDB
apo-DoxazosinMeSH, HMDB
Azupharma brand OF doxazosin mesylateMeSH, HMDB
CarduranMeSH, HMDB
Doxa-purenMeSH, HMDB
DoxaUroMeSH, HMDB
DoxamaxMeSH, HMDB
DoxazomerckMeSH, HMDB
Doxazosin azuMeSH, HMDB
Doxazosin apogephaMeSH, HMDB
Doxazosin klastMeSH, HMDB
Doxazosin stadaMeSH, HMDB
Doxazosina alterMeSH, HMDB
Doxazosina cinfaMeSH, HMDB
MTW Brand OF doxazosin mesylateMeSH, HMDB
Mesylate, doxazosinMeSH, HMDB
novo-DoxazosinMeSH, HMDB
Novopharm brand OF doxazosin mesylateMeSH, HMDB
Pfizer brand OF doxazosin mesylateMeSH, HMDB
Pharmagenus brand OF doxazosin mesylateMeSH, HMDB
Q Pharm brand OF doxazosin mesylateMeSH, HMDB
Ratiopharm, doxazosinaMeSH, HMDB
Wolff brand OF doxazosin mesylateMeSH, HMDB
Wörwag brand OF doxazosin mesylateMeSH, HMDB
Betapharm brand OF doxazosin mesylateMeSH, HMDB
CT Arzneimittel brand OF doxazosin mesylateMeSH, HMDB
Esparma brand OF doxazosin mesylateMeSH, HMDB
CT, Doxazosin vonMeSH, HMDB
Von CT, doxazosinMeSH, HMDB
Chemical FormulaC23H25N5O5
Average Molecular Weight451.4751
Monoisotopic Molecular Weight451.185568935
IUPAC Name2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
Traditional Namedoxazosin
CAS Registry Number74191-85-8
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
InChI Identifier
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
InChI KeyRUZYUOTYCVRMRZ-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Quinazolinamine
  • Diazanaphthalene
  • Benzo-1,4-dioxane
  • Benzodioxane
  • Quinazoline
  • Anisole
  • Dialkylarylamine
  • Alkyl aryl ether
  • Aminopyrimidine
  • Para-dioxin
  • Pyrimidine
  • Imidolactam
  • Benzenoid
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Carboxamide group
  • Amino acid or derivatives
  • Oxacycle
  • Azacycle
  • Carboxylic acid derivative
  • Ether
  • Organic oxygen compound
  • Amine
  • Carbonyl group
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Primary amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Ontology
Disposition

Biological location

Source

Route of exposure

Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point289 - 290 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.79 g/LNot Available
LogP2.1Not Available
Experimental Spectral Properties

Experimental Collision Cross Sections

PredictorAdduct TypeData SourceCCS Value (Å2)Reference
DeepCCS[M+H]+CBM202.930932474
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.79 g/LALOGPS
logP10(2.53) g/LALOGPS
logP10(2.14) g/LChemAxon
logS10(-2.8) g/LALOGPS
pKa (Strongest Acidic)12.67ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area112.27 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity121.64 m³·mol⁻¹ChemAxon
Polarizability46.63 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Spectral Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+206.04431661259
DarkChem[M-H]-203.20731661259

Predicted Kovats Retention Indices

Not Available
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Doxazosin GC-MS (Non-derivatized) - 70eV, Positivesplash10-000i-0792300000-541be6ba12e92be793212017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Doxazosin GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Doxazosin GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , negative-QTOFsplash10-0udi-0010900000-9601aa919c95799ec0092017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , negative-QTOFsplash10-0kei-0981100000-a9ee3121ba6832366f8e2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , negative-QTOFsplash10-0a4i-0970000000-5261f1bc60ceee4364de2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , negative-QTOFsplash10-0a4i-0950000000-f649236044e4e2a5de382017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , negative-QTOFsplash10-0a4i-1920000000-86655cc3bb892d7570682017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , negative-QTOFsplash10-0a4i-1900000000-88bca2ddf2930fa0c4682017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , positive-QTOFsplash10-0udi-0000900000-449254642300c13242852017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , positive-QTOFsplash10-0udi-0002900000-3097c8a3403b526109182017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , positive-QTOFsplash10-0006-0079100000-06d36a9b7afe6cf0c6e92017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , positive-QTOFsplash10-000t-1091000000-cbd9b2106818ef5fd2ba2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , positive-QTOFsplash10-001i-1190000000-a1c84b0c3657d8000e352017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin LC-ESI-QFT , positive-QTOFsplash10-001i-1390000000-e802cb93ca8d6934ee962017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin 30V, Positive-QTOFsplash10-0udi-0002900000-4bf3463746e5cedb45822021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin 15V, Positive-QTOFsplash10-0udi-0000900000-439134f282b4b9ac6da02021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin 45V, Positive-QTOFsplash10-0006-0079100000-e52fef19f2d7df13686f2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin 60V, Positive-QTOFsplash10-000t-1091000000-8545cbf9afb97ce44d202021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin 60V, Negative-QTOFsplash10-0a4i-0950000000-1a542e27420bd69823af2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin 45V, Negative-QTOFsplash10-0a4i-0970000000-7ca89cc9e15bcae386a02021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Doxazosin 15V, Negative-QTOFsplash10-0udi-0010900000-6e481ed6a67e73c1a9e42021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Doxazosin 10V, Positive-QTOFsplash10-0udi-1020900000-64c5e9c37f904260cdbd2016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Doxazosin 20V, Positive-QTOFsplash10-0f6x-1387900000-1564571c4e6f2bd227992016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Doxazosin 40V, Positive-QTOFsplash10-0032-5090000000-29e9f7a134a59719b1e72016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Doxazosin 10V, Negative-QTOFsplash10-0udi-0213900000-03663ba73cebf8b1bbb72016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Doxazosin 20V, Negative-QTOFsplash10-0h3i-0494500000-e01cd92097617b53acea2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Doxazosin 40V, Negative-QTOFsplash10-059f-4193000000-4a19be62579d7f7008952016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Extracellular
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00590 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00590 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00590
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID3045
KEGG Compound IDC06970
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkDoxazosin
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI ID4708
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]

Enzymes

General function:
Involved in monooxygenase activity
Specific function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular weight:
55944.565
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in monooxygenase activity
Specific function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular weight:
55768.94
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in ion channel activity
Specific function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoform 3 has no channel activity by itself, but modulates channel characteristics when associated with isoform 1
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular weight:
126653.5
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
General function:
Involved in ion channel activity
Specific function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current. Channel properties may be modulated by cAMP and subunit assembly
Gene Name:
KCNH6
Uniprot ID:
Q9H252
Molecular weight:
109923.7
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular weight:
51486.0
References
  1. Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J: Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol. 2004 Oct;82(10):872-8. [PubMed:15573147 ]
  2. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427 ]
  3. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264 ]
  4. Ishizuka O, Pandita RK, Mattiasson A, Steers WD, Andersson KE: Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):787-93. [PubMed:9205965 ]
  5. Bae JH, Jung PB, Lee JG: The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int. 2005 Nov;96(7):1131-5. [PubMed:16225542 ]
  6. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  7. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  8. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular weight:
56835.4
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular weight:
60462.2
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
General function:
Involved in ion channel activity
Specific function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly
Gene Name:
KCNH7
Uniprot ID:
Q9NS40
Molecular weight:
134998.5
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Transporters

General function:
Involved in ATP binding
Specific function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular weight:
141477.3
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]